BOSTON, MASSACHUSETTS, U.S., April 24, 2017 /EINPresswire.com/ -- Soft tissues are body tissues that are not hardened or calcified, this includes tendon, muscle, skin, fat, and fascia. They typically connect, support, or surround bone and internal organs. Injury to soft tissue can be caused either due to sudden trauma or due to overuse of a particular part of the body. The soft tissue repair treatment is dependent on the type of injury and severity. Minor injuries are recovered on their own or with the use of mild treatment methods such as RICE that is rest, ice, compression and elevation. While, other severe injuries or conditions such as hernia, valve stenosis, third degree burns, ligament tears, etc., may require surgical repairs. As estimated by IQ4I Research, the soft tissue repair global market is expected to grow at CAGR of a high end single digit to reach $21,319.7 million by 2023.

Ageing is associated with a decline in muscle mass, strength, number of muscle fibres, changes in muscle contraction and slowing of nerve fibers that activate muscle making them prone to soft tissue injuries. Patients who experience extended immobility, as in the case of obese population, and ones who are at risk for developing chronic wounds or tissue damage, will increase the number of potential patients and thereby increase the number of medical procedures to repair the tissue damages. With substantial reduction in communicable diseases and advancements that are helping in preventing communicable diseases, the world is witnessing a shift towards lifestyle diseases such as cardiovascular diseases and injuries due to recreational sports activities. There has been an explosion in cardiovascular diseases (CVDs) that has reached alarming proportions. Along with these factors, increase in healthcare expenditure and growing emerging markets across the globe is driving the soft tissue repair market.

Agencies like U.S. Medicare, Medicaid, and U.K. NHS provide reimbursement for a wide range of procedures that include soft tissue repair. Reimbursements are provided only for essential procedures like hernia repair or cardiac repair, while, non-essential procedures or cosmetic procedures like breast reconstruction and dental repair have limited or no reimbursement. Also, products used in soft tissue repair are highly regulated from the beginning to the end of the manufacturing process to their distribution, due to stringently regulations that demands the need for specialized equipment and facilities for manufacture and distribution, which in turn adds to the cost of the product. The high cost of the procedure is also due to low availability of raw materials for the products that are required for such procedures. These factors hinder the growth of the soft tissue repair market.

The soft tissue global market is segmented into products, surgery, applications and geography. The products market is further divided into meshes/tissue patches, fixation devices, cardiac repair devices and others. The cardiac repair devices segment accounted largest share, due to technological advancements, increasing awareness, etc.

Based on the surgery, the soft tissue repair global market is segmented into open surgery and minimally invasive surgery. Although, open surgery is the traditional form of most surgeries, minimally invasive surgeries are taking over the market in the case of soft tissue repair. Minimally invasive surgery thus accounts for the largest share in this segment.
Soft tissue repair global market is classified by application into hernia repair, dental reconstruction, vaginal sling procedures, skin repair, breast reconstruction, orthopedic, cardiac repair, and others. Cardiac repair segment accounted for the largest share, as aged population who are prone to cardiovascular diseases such as cardiac valve stenosis, aneurysm and other cardiac related problems are expected to rise. Skin repair is the fastest growing segment due to increased awareness especially in cases such as diabetic foot ulcers and treatment options.

The soft tissue repair global market based on geography is divided into North America, Europe, Asia-Pacific and Rest of the world. North America region commanded the largest revenue market share. However, Asia- Pacific region is expected to grow at the highest due to rising awareness, higher economic growth, large patient pool and rising aged population.

Technological advancements are taking place in terms of the source of materials used as skin graft. For an instance, Kerecis has developed the unique, patented Kerecis Omega3 fish-skin transplantation technology, where intact fish skin is used for tissue regeneration. The Kerecis Omega3 transplantation technology is used to reconstruct tissue damage in applications such as burn and diabetic wounds as well as for oral wounds, hernia repair, breast reconstruction and for dura restoration. Other tissue-transplant products are based on tissues of human and porcine origin. Corin Group PLC has taken source of material one step ahead with the development of Ligament Augmentation & Reconstruction System (LARS). LARS is a range of synthetic ligament argumentation device that is suitable for various applications in sports medicine such as ACL and Achilles tendon repair.

Other advancements such as improved technology for better fixation of devices, for example Stryker developed SonicAnchor, the only implant in the U.S. market which utilizes ultrasonic energy. Unlike traditional suture anchor fixation, the product’s design and SonicFusion technology are good as they may lower risk of breakage during insertion and offers high pull-out strength and reliability. Also, the application of ultrasonic energy liquefies the tip of the SonicAnchor, a bioresorbable polylactide polymer, enabling it to flow into cancellous bone cavities for stable fixation within five seconds after application. Similarly, polymeric heart valves, 3D printing, cardiac or ventricular remodeling, sutureless valves and catheter based valves for cardiac repair specifically are some devices with enhanced technology.

The soft tissue repair market is consolidated because the majority of the soft tissue repair market is occupied by players such as Edwards Lifesciences, Abbott Laboratories, Arthrex Inc, Medtronic PLC, and Allergan (Lifecell).
Major players in soft tissue repair market include Edwards Lifesciences (U.S.), Medtronic PLC (Ireland), Abbott Laboratories (U.S.), Arthrex Inc (U.S.), Johnson & Johnson (U.S.), C.R. Bard Inc, (U.S.), Allergan (Lifecell) (U.S.), Smith & Nephew (U.K.), Integra Lifesciences (U.S.), Livanova (U.K.), Zimmer Biomet (U.S.), Organogenesis (U.S.), etc.

Some of the other companies operating in soft tissue repair global market include, Abiss (Switzerland), Admedus (Australia), Advanced Medical Solutions Group PLC (U.K.), Angiologica BM Srl (Italy), Aroa (New Zealand), Aspide Medical (France), B.Braun (Germany), Braile bio medica (Brazil), Betatech Medical (Turkey), Changzhou DAHUA Corp., Ltd (China), Coloplast (Denmark), Inion Oy (Finland), Kerecis (Iceland), Lotus Surgical Pvt Ltd (India), Novus Scientific (Singapore), Occlutech (Sweden), S & G Biotech, Inc. (South Korea), Strait Access Technologies Pty Ltd (South Africa), Valcare Medical (Israel), Medtentia International Ltd Oy (Finland), etc.

Mr. Sattish Biruddukota
IQ4I Research & Consultancy Pvt Ltd.,
+91-80-60500229
email us here